88. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat
Rev Urol 2013;10: 38–48.
89. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al.
Early detection of prostate cancer: AUA Guideline. J Urol 2013;190:419–26.
90. Bleyer A, Welch HG. Effect of three decades of screening mammography
onbreast-cancer incidence. N Engl J Med 2012;367:1998–2005.
91. National Lung Screening Trial Research Team. Church TR, Black WC, Aberle
DR, Berg CD, Clingan KL, Duan F, et al. Results of initial low-dose computed
tomographic screening for lung cancer. N Engl J Med 2013;368:1980–91.
92. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg
CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose
computed tomographic screening. N Engl J Med 2011;365:395–409.
93. Bach PB, Gould MK. When the average applies to no one: personalized
decision making about potential benefits of lung cancer screening. Ann
Intern Med 2012;157:571–3.
94. Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening
campaigns—getting past uninformative persuasion. N Engl J Med
95. National Cancer Institute. Cancer survivorship research. [cited 2013 July
31]; Available from: http://cancercontrol.cancer.gov/ocs/
96. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann
B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A
comparison of letrozole and tamoxifen in postmenopausal women with early
breast cancer. N Engl J Med 2005;353:2747–57.
97. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al., for the
ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in
Combination) trial after completion of 5 years’ adjuvant treatment for breast
cancer. Lancet 2005;365: 60–2.
98. Early Breast Cancer Trialists’ Collaborative Group, Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke
M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors
and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771–84.
99. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term
effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5
years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a
randomised trial. Lancet 2013;381:805–16.
100. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. a TTom:
Long-term effects of continuing adjuvant tamoxifen to 10 years versus
stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol
31: 5, 2013 (suppl).
101. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al.
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl
J Med 2012;367:1596–606.
102. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of
colorectal cancer. JAMA 2009;302:649–58.
103. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A
randomized trial of aspirin to prevent colorectal adenomas in patients with
previous colorectal cancer. N Engl J Med 2003;348:883–90.
104. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al.
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl
J Med 2013;369:213–23.
105. Pardoll DM. Immunology beats cancer: a blueprint for successful translation.
Nat Immunol 2012;13:1129–32.
106. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
Improvedsurvival with ipilimumab in patients with metastatic melanoma. N
Engl J Med 2010;363:711–23.
107. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et
al. Four-year survival rates for patients with metastatic melanoma who
received ipilimumab in phase II clinical trials. Ann Oncol 2013;24:2174–80.
108. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et
al. Ipilimumab in combination withpaclitaxel and carboplatin as first-line
treatment instage IIIB/IV non–small-cell lung cancer: Results from a
randomized, double-blind, Multicenter Phase II Study. Journal of Clinical
109. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et
al. Ipilimumab alone or in combination with radiotherapy in metastatic
castration-resistant prostate cancer: results from an open-label, multicenter
phase I/II study. Ann Oncol 2013;24:1813–21.
110. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott
DF, et al. Safety, activity, andimmune correlates of anti–PD- 1 antibody in
cancer. N Engl J Med 2012;366:2443–54.
111. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al.
Safety and activity of ati–PD-L1 antibody in patients with advanced cancer.
N Engl J Med 2012;366:2455–65.
112. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al.
Durable cancer regression off-treatment and effective reinduction therapy
with an anti-PD- 1 antibody. Clin Cancer Res 2013;19:462–8.
113. Brahmer JR, Horn L, Antonia SJ, Spigel DR, Gandhi L, Sequist LV, et
al. Survival and long-term follow-up of the phase I trial of nivolumab
(Anti-PD- 1; BMS-936558; ONO-4538) in patients (pts) with previously
treated advanced non-small cell lung cancer (NSCLC). ASCO Meeting
114. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and
tumor responses with lambrolizumab (anti–PD- 1) in melanoma. N Engl J
115. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM,
et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med
116. Hodi FS, Lee SJ, McDermott DF, Rao UNM, Butterfield LH, Tarhini AA, et
al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab
(Ipi) versus ipi alone in metastatic melanoma: E1608. J Clin Oncol
117. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.
Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. N Engl
J Med 2010;363:411–22.
118. Small EJ, Lance RS, Redfern CH, Millard FE, Gardner TA, Karsh LI, et al.
A randomized phase II trial of sipuleucel-T with concurrent or sequential
abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant
prostate cancer (mCRPC). J Clin Oncol 31, 2013 (suppl; abstr 5047).
119. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M,
et al. A randomized phase II study of immunization with dendritic cells
modified with poxvectors encoding CEA and MUC1 compared with the same
poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg
2013 May 7. [Epub ahead of print].
120. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M,
et al. Overall survival analysis of a phase II randomized controlled trial of
a poxviral-based PSA—targeted immunotherapy in metastaticcastration-resistant prostatecancer. J Clin Oncol 2010;28:1099–105.
121. Le DT, Wang-Gillam A, Picozzi VJ, Greten TF, Crocenzi TS, Springett GM, et
al. Interim safety and efficacy analysis of a phase II, randomized study of
GVAX pancreas and CRS-207 immunotherapy in patients with metastatic
pancreatic cancer. J Clin Oncol 31, 2013 (suppl; abstr 4040).
122. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells
with chimeric antigen receptors have potent antitumor effects and can
establish memory in patients with advanced leukemia. Science Transl Med
123. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I,
et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–
transduced T cells. Blood 2012;119:2709–20.
124. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al.
CD19-Targeted T cells rapidly induce molecular remissions in adults with
chemotherapy-refractory acute lymphoblastic leukemia. Science Transl Med